clinical trial · NCT06100237
Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
Carl Ola Landgren, MD, PhD·phase2·recruiting·n = 50
Multiple MyelomaTeclistamabTalquetamabDaratumumab SC
brief summary
The purpose of this study is to see whether combination treatment of Teclistamab and Daratumumab (Tel-Dara) or combination Talquetamab and Daratumumab (Tal-Dara) will delay the onset of multiple myeloma.
started
Dec 4, 2023
primary completion
Dec 31, 2028
completion
Dec 31, 2029
last updated
Feb 23, 2026
official title
Teclistamab or Talquetamab in Combination With Daratumumab SC for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Sequential Cohort Immuno-Oncology Study to REVIVE Early Myeloma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol